MISSD pushes for clearer akathisia warnings as awareness grows

By AI, Created 10:04 AM UTC, May 20, 2026, /AGP/ – MISSD is urging stronger drug risk disclosure and better clinician education as public attention on akathisia rises after coverage involving Jordan Peterson. The advocacy push includes a petition for black box warnings, new free training courses, and more patient reporting tools.

Why it matters: - Akathisia can be severe and is often missed, which can delay treatment and worsen harm. - MISSD says clearer warnings and better recognition could reduce misdiagnosis, inappropriate medication changes, and preventable injury. - The issue matters beyond psychiatry because akathisia has been linked to hundreds of medications used for multiple conditions.

What happened: - MISSD called for improved drug risk disclosure and stronger clinical awareness after renewed media coverage of akathisia tied to Jordan Peterson. - Public accounts shared by Peterson’s daughter, Mikhaila Peterson, said he has experienced symptoms consistent with akathisia. - Patient safety advocacy efforts also picked up around a Change.org petition launched by akathisia survivor Stacey Haza. - Haza said she was not fully warned about the risk and is seeking black box warnings that explicitly name and describe akathisia. - Black box warnings are the U.S. Food and Drug Administration’s most serious safety warnings and signal potentially life-threatening risks.

The details: - Wendy Dolin, MISSD founder, said akathisia is not clearly disclosed in current drug labeling and that delayed recognition contributes to misdiagnosis. - Akathisia can involve severe inner agitation, an inability to sit still, panic, insomnia, and intense psychological distress. - The condition may occur with or without visible movement. - Severe cases have been associated with self-harm, violence and suicide. - Akathisia is often minimized as “restlessness” and misdiagnosed as an underlying psychiatric condition instead of an adverse drug effect. - MISSD says akathisia has been associated with dopamine-blocking medications, including certain anti-nausea drugs. - Other medication groups linked to akathisia include some anti-infective and antimalarial drugs, antidepressants, antipsychotics, certain acne or hair-loss treatments, and other central nervous system drugs. - Haza described the experience as feeling like she was “crawling out of my skin” and being afraid of “literally everything.” - Haza said one common message in the prescribed-harm community is, “I wish someone had told me—I wish I had known.” - MISSD said Haza was misdiagnosed and mistreated after developing akathisia. - Haza discusses her experience on MISSD’s Akathisia Stories podcast. - Haza also promotes akathisia awareness and informed consent through her YouTube channel, social media and her Change.org petition. - An online platform, prescribed-harm.com, allows people to share experiences related to akathisia and iatrogenic harm. - MISSD offers two free online courses for healthcare professionals, patients, caregivers and families worldwide. - The courses are titled “Addressing Clinicians’ Challenges and Misunderstandings About Akathisia” and “Akathisia 101.” - “Akathisia 101” is accredited by the National Association of Social Workers and offers 1 CE credit. - Both courses take about one hour to complete. - Access to the courses is available online.

Between the lines: - The campaign is trying to shift akathisia from a vague side effect to a named, disclosed risk that clinicians and patients can recognize earlier. - Peterson’s visibility is expanding public awareness, but MISSD is using that attention to push for formal labeling changes and training. - The focus on informed consent suggests advocates see education as a core patient-safety tool, not an optional add-on.

What’s next: - MISSD is steering readers to its podcasts, online courses and educational resources to broaden awareness. - Haza’s petition and public advocacy are likely to keep pressure on regulators and prescribers to improve warnings. - MISSD says it will continue promoting akathisia education for healthcare professionals and families worldwide. - The foundation says it accepts no funding from the pharmaceutical industry.

The bottom line: - MISSD wants akathisia treated as a clearly labeled medication risk, not an overlooked symptom, and it is using new public attention to press for faster action.